Information About Cancer

Breast cancer type

Breast cancer type is categorized by whether it begins in the ducts or lobules, the organs responsible for breast milk production. Medullary carcinoma accounts for 15% of all breast cancer types. This breast cancer type represents 5% of all diagnosis. IPR015525 Breast cancer type 2 susceptibility protein Header EBIDatabasesInterPro Search Open in usermanual InterPro: ” /> Jump to: InterProScan Databases Documentation FTP site Help Click on the icon for context sensitive help from the user manual. The breast cancer type 2 susceptibility protein (BRCA2) is a breast tumour suppressor with a potential function in the cellular response to DNA damage. Some breast cancer types express one or more of these proteins on their cell surface, while others express none. Media Relations Contacts Online Press Kit Rumors, Myths, and Truths Glossary About the American Cancer Society Breastfeeding, Other Factors May Affect Risk of Breast Cancer TypeAtlanta 2008/08/25 -Factors such as age at menopause as well as a woman?s breastfeeding practices can influence her risk of developing certain types of breast cancer.

Read the full story

http://bilalhealthclinic.com/breastcancer.html

Breast cancer is a cancer that starts in the breast, usually in the inner lining of the milk ducts or lobules. There are different types of breast cancer, with different stages (spread), aggressiveness, and genetic makeup. With best treatment, 10-year disease-free survival varies from 98% to 10%. Treatment includes surgery, drugs (hormone therapy and chemotherapy), and radiation.

Worldwide, breast cancer is the second most common type of cancer after lung cancer (10.4% of all cancer incidence, both sexes counted)[ and the fifth most common cause of cancer death. In 2004, breast cancer caused 519,000 deaths worldwide (7% of cancer deaths; almost 1% of all deaths).

Breast cancer is about 100 times as frequent among women as among men, but survival rates are equal in both sexes.

Some breast cancers require the hormones estrogen and progesterone to grow, and have receptors for those hormones. Those cancers are treated with drugs that interfere with those hormones, usually tamoxifen, and with drugs that shut off the production of estrogen in the ovaries or elsewhere; this may damage the ovaries and end fertility. Low-risk, hormone-sensitive breast cancers may be treated with hormone therapy and radiation alone. Breast cancers without hormone receptors, or which have spread to the lymph nodes in the armpits, or which express certain genetic characeristics, are higher-risk, and are treated more aggressively. One standard regimen, popular in the U.S., is cycophosphamide plus doxorubicin (Adriomycin), known as CA; these drugs damage DNA in the cancer, but also in fast-growing normal cells where they cause serious side effects. Sometimes a taxane drug, such as docetaxel, is added, and the regime is then known as CAT; taxane attacks the microtubules in cancer cells. An equivalent treatment, popular in Europe, is cyclophosphamide, methotrexate, and fluorouracil (CMF). Monoclonal antibodies, such as trastuzumab, are used for cancer cells that have the HER2 mutation. Radiation is usually added to the surgical bed to control cancer cells that were missed by the surgery, which usually extends survival, although radiation exposure to the heart may cause damage and heart failure in the following years.

Breast cancers are described along four different classification schemes, or groups, each based on different criteria and serving a different purpose:

Pathology - Each tumor is classified by its histological (microscopic anatomy) appearance and other criteria.
Grade of tumor – The histological grade of a tumor is determined by a pathologist under a microscope. A well-differentiated (low grade) tumor resembles normal tissue. A poorly differentiated (high grade) tumor is composed of disorganized cells and, therefore, does not look like normal tissue. Moderately differentiated (intermediate grade) tumors are somewhere in between.
Protein & gene expression status – Currently, all breast cancers should be tested for expression, or detectable effect, of the estrogen receptor (ER), progesterone receptor (PR) and HER2/neu proteins. These tests are usually done by immunohistochemistry and are presented in a pathologist’s report. The profile of expression of a given tumor helps predict its prognosis, or outlook, and helps an oncologist choose the most appropriate treatment. More genes and/or proteins may be tested in the future.
Stage of a tumor – The currently accepted staging scheme for breast cancer is the TNM classification. This considers the Tumor itself, whether it has spread to lymph Nodes, and whether there are any Metastases to locations other than the breast and lymph nodes. Read the full story

Important news For Breast Cancer

Breast cancer can affect one in eight women, and is the leading cause of cancer-related deaths in the United States, second only to lung cancer. There doesn’t seem to be any definitive prevention for breast cancer, but there are certain risk factors that make women susceptible, including age and genetics. Women with genes BRCA1 and BRCA2, or women that have family history of breast cancer, should get tested regularly.

A breast self-examination once a month is a good way to catch lumps before they become bigger problems. The best way to examine is to make note of nipple size, skin tone, and differences in size. Since most breasts can already feel lumpy, look for lumps that are not regularly on the breast, or if there is thickening around the nipple. Breasts should be checked with three fingers in a clockwise motion, both standing and lying on your side. Check the whole breast area, including under the breasts and up to the armpits.

Read the full story